Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

被引：0

作者：

Vanna Chiarion-Sileni

Paola Del Bianco

Antonella Romanini

Michele Guida

Adriano Paccagnella

Maurizio Dalla Palma

Emanuele Naglieri

Ruggero Ridolfi

Barbara Silvestri

Maria Michiara

Gian Luca De Salvo

机构：

[1] University Hospital,Department of Medical Oncology

[2] Istituto Oncologico Veneto,Clinical Trials and Biostatistics Unit

[3] S. Chiara Hospital,Medical Oncology Unit

[4] Ospedale Oncologico,Medical Oncology Unit

[5] SS Giovanni e Paolo Hospital,Medical Oncology Unit

[6] S. Bortolo Hospital,Medical Oncology Unit

[7] Pierantoni Hospital,Oncology Dept

[8] General Hospital,Medical Oncology Unit

[9] General Hospital,Medical Oncology Unit

来源：

BMC Cancer | / 6卷

关键词：

Melanoma; Granisetron; High Dose Interferon; Actual Dose Intensity; Lymphatic Basin Drainage;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 44 条

[1] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI-Mel.A.) [ISRCTN75125874]
Chiarion-Sileni, V
Del Bianco, P
Romanini, A
Guida, M
Paccagnella, A
Dalla Palma, M
Naglieri, E
Ridolfi, R
Silvestri, B
Michiara, M
De Salvo, GL
[J]. BMC CANCER, 2006, 6 (1)
[2] Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]
Chiarion-Sileni, V.
Guida, M.
Romanini, A.
Ridolfi, R.
Mandala, M.
Del Bianco, P.
Silvestri, B.
Medici, M.
Michiara, M.
Dalla Palma, M.
Puccetti, O.
Pigozzo, J.
Laveder, F.
De Salvo, G. L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3] Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
Eggermont, Alexander M. M.
Suciu, Stefan
Testori, Alessandro
Santinami, Mario
Kruit, Wim H. J.
Marsden, Jeremy
Punt, Cornelis J. A.
Sales, Francois
Dummer, Reinhard
Robert, Caroline
Schadendorf, Dirk
Patel, Poulam M.
de Schaetzen, Gaetan
Spatz, Alan
Keilholz, Ulrich
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) : 3810 - 3818
[4] Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
Mohr, Peter
Hauschild, Axel
Trefzer, Uwe
Enk, Alexander
Tilgen, Wolfgang
Loquai, Carmen
Gogas, Helen
Haalck, Thomas
Koller, Josef
Dummer, Reinhard
Gutzmer, Ralf
Brockmeyer, Norbert
Hoelzle, Erhard
Sunderkoetter, Cord
Mauch, Cornelia
Stein, Annette
Schneider, Lars A.
Podda, Maurizio
Goeppner, Daniela
Schadendorf, Dirk
Weichenthal, Michael
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4077 - +
[5] Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients
Weichenthal, Michael
Chiarion-Sileni, Vanna
Hauschild, Axel
Del Bianco, Paola
Trefzer, Uwe
Guida, Michele
Enk, Alexander
Romanini, Antonella
Loquai, Carmen
Ridolfi, Ruggero
Schadendorf, Dirk
Mandala, Mario
Koller, Josef
Silvestri, Barbara
Gogas, Helen
Medici, Michele
Dummer, Reinhard
De Salvo, Gian Luca
Mohr, Peter
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[6] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Eggermont, Alexander M. M.
Suciu, Stefan
Santinami, Mario
Testori, Alessandro
Kruit, Wim H. J.
Marsden, Jeremy
Punt, Cornelis J. A.
Sales, Francois
Gore, Martin
MacKie, Rona
Kusic, Zvonko
Dummer, Reinhard
Hauschild, Axel
Musat, Elena
Spatz, Alain
Keilholz, Ulrich
[J]. LANCET, 2008, 372 (9633): : 117 - 126
[7] Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
Bottomley, Andrew
Coens, Corneel
Suciu, Stefan
Santinami, Mario
Kruit, Willem
Testori, Alessandro
Marsden, Jeremy
Punt, Cornelis
Sales, Francois
Gore, Martin
MacKie, Rona
Kusic, Zvonko
Dummer, Reinhard
Patel, Poulam
Schadendorf, Dirk
Spatz, Alain
Keilholz, Ulrich
Eggermont, Alexander
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 2916 - 2923
[8] Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma
Mitchell, Malcolm S.
Abrams, Judith
Thompson, John A.
Kashani-Sabet, Mohammed
DeConti, Ronald C.
Hwu, Wen-Jen
Atkins, Michael B.
Whitman, Eric
Ernstoff, Marc S.
Haluska, Frank G.
Jakowatz, James G.
Das Gupta, Tapas K.
Richards, Jon M.
Samlowski, Wolfram E.
Costanzi, John J.
Aronson, Frederick R.
Deisseroth, Albert B.
Dudek, Arkadiusz Z.
Jones, Vicky E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 2078 - 2085
[9] Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
Kirkwood, JM
Strawderman, MH
Ernstoff, MS
Smith, TJ
Borden, EC
Blum, RH
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 7 - 17
[10] Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group (vol 27, pg 2916, 2009)
Bottomley
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4630 - 4630

← 1 2 3 4 5 →